Camille L Bedrosian
CIK 1326969 · Chief Medical Officer · last filed 2026-06-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$9.12M
Companies
5
Total Filings
49
Lifetime Open-Market Net
-$6.51M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRNX | Director | 22,225 | $83.86 | $1.86M | $0 | 7 | 2026-06-22 |
| AMLX | Chief Medical Officer | 265,285 | $19.55 | $5.19M | -$473.8K | 10 | 2026-03-09 |
| RYTM | Director | 7,000 | $108.04 | $756.3K | $0 | 8 | 2025-06-26 |
| RARE | EVP and Chief Medical Officer | 50,601 | $25.98 | $1.31M | -$6.04M | 19 | 2023-03-03 |
| ARIAD PHARMACEUTICALS INC (ARIA) Delisted | VP, Chief Medical Officer | — | — | — | $0 | 1 | 2007-04-18 |
Recent Filings · Page 2 of 5
49 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-23 | RYTM | Exer (M) | +4,000 | $0 | EDGAR |
| 2025-06-13 | CRNX | Grant (A) | +6,900 | $0 | EDGAR |
| 2025-04-02 | AMLX | Sell (S) | −12,425 | -$43.1K | EDGAR |
| 2025-03-10 | AMLX | Grant (A) | +68,420 | $0 | EDGAR |
| 2024-12-03 | AMLX | Sell (S) | −5,421 | -$30.0K | EDGAR |
| 2024-10-02 | AMLX | Sell (S) | −11,442 | -$36.6K | EDGAR |
| 2024-06-25 | RYTM | Exer (M) | +3,000 | $0 | EDGAR |
| 2024-06-20 | RYTM | Grant (A) | — | $0 | EDGAR |
| 2024-06-11 | CRNX | Grant (A) | +3,400 | $0 | EDGAR |
| 2024-04-18 | AMLX | Grant (A) | +96,910 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.